← Research

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review

Orsini CA, Wong J, Di Luch M, et al. — University of Toronto

Published in JAMA Psychiatry

Reviewed 112 randomized psychedelic trials and found only 29.5% even assessed whether blinding held — but 57.1% cited it as a limitation anyway. Among the trials that did check: psilocybin, LSD, and ayahuasca trials reported blinding-failure rates above 90%; inert-placebo MDMA trials exceeded 85%. No control strategy — active placebo or otherwise — consistently preserved blinding across the trials reviewed.

Read the Full Paper at JAMA Psychiatry